公开(公告)号：US20190376973A1

公开(公告)日：2019-12-12

申请号：US16548756

申请日：2019-08-22

Applicant: Spring BioScience Corporation

Inventor： Fernando Jose Rebelo do Couto ,  Zhiming Liao ,  Yifei Zhu

IPC: G01N33/573 ,  G01N33/574 ,  C12N9/96 ,  C12N9/02 ,  C07K16/40

Abstract: The invention provides antibodies that bind specifically to human indoleamine 2,3-dioxygenase 1 (IDO1), nucleic acids encoding the same, and methods of using the same. The antibodies are capable of binding to a sequence comprising SEQ ID NO: 1 and specifically bind to human IDO1 in formalin fixed paraffin embedded tissues. The antibodies are useful in a number of different analytical techniques, including immunohistochemistry (IHC) and immunocytochemistry (ICC).

公开(公告)号：US20180196057A1

公开(公告)日：2018-07-12

申请号：US15851502

申请日：2017-12-21

Applicant: Ventana Medical Systems, Inc. ,  Spring BioScience Corporation

Inventor： Fernando Jose Rebelo do Couto ,  Zhiming Liao ,  Andrea Muranyi ,  Kandavel Shanmugam ,  Shalini Singh ,  Yifei Zhu

IPC: G01N33/574 ,  C07K16/22 ,  C07K16/30

CPC classification number: G01N33/57496 ,  C07K16/22 ,  C07K16/30 ,  C07K2317/20 ,  C07K2317/34 ,  C07K2317/92 ,  G01N2333/485

Abstract: The invention provides anti-human pro-epiregulin and anti-human amphiregulin antibodies and methods of using the same. Anti-EREG antibodies raised against amino acids 148-169 and 156-169 of the human EREG protein, and anti-AREG antibodies raised against amino acids 238-252 of the human AREG protein are disclosed. Methods of using these antibodies to detect EREG and AREG and kits and other products for performing such methods are also disclosed.

公开(公告)号：US09885721B2

公开(公告)日：2018-02-06

申请号：US14725953

申请日：2015-05-29

Applicant: Spring BioScience Corporation

Inventor： Fernando Jose Rebelo do Couto ,  Zhiming Liao ,  Yifei Zhu

IPC: C07K16/28 ,  C07K16/30 ,  G01N33/574

CPC classification number: G01N33/57492 ,  C07K16/2827 ,  C07K16/2896 ,  C07K2317/34 ,  C07K2317/51 ,  C07K2317/515 ,  C07K2317/92 ,  G01N2333/70596

Abstract: Provided herein are PD-L1 antibodies and methods for using the same for diagnosing a medical condition associated with elevated PD-L1 levels (e.g., cancer) in subjects in need thereof and antigen binding fragments thereof. The PD-L1 antibodies and antigen binding fragments are also useful in evaluating the efficacy of a particular therapeutic regime in a subject diagnosed as having a PD-L1-related medical condition.

公开(公告)号：US20180031566A1

公开(公告)日：2018-02-01

申请号：US15782804

申请日：2017-10-12

Applicant: Spring BioScience Corporation

Inventor： Fernando Jose Rebelo do Couto ,  Zhiming Liao ,  Yifei Zhu

IPC: G01N33/574 ,  C07K16/28

CPC classification number: G01N33/57492 ,  C07K16/28 ,  C07K16/30 ,  C07K2317/565 ,  C07K2317/567 ,  G01N1/30

Abstract: Antibodies, compositions, systems, and methods for detecting C4.4a, for example immunohistochemistry methods for detecting C4.4a using a C4.4a antibody. The antibody may be obtained by immunizing a host with a C4.4a protein such as a peptide downstream of the signal peptide. The antibodies may be adapted to detect the uPAR-like domain 1 and uPAR-like domain 2. Also featured are methods for diagnosing C4.4a-associated tumors using C4.4a antibodies disclosed herein.